美国大麻行业领导人敦促科学严谨和FDA标准, Cannabis leaders urge scientific rigor and FDA standards for safety over legalization.

2026年4月20日,大麻行业领导人强调需要科学严谨性来推动合法化. On April 20, 2026, cannabis industry leaders emphasize the need for scientific rigor over legalization advocacy. 国际药品管理公司倡导遵守FDA标准以确保安全性和有效性,并警告说没有临床验证的补偿可能会破坏药物安全政策. MMJ International Holdings advocates for adherence to FDA standards to ensure safety and efficacy, warning that reimbursement without clinical validation risks undermining drug safety policies. 公司认为大麻医药的未来必须建立在证据, 而不是作上, 将一般获取和经过验证的植物疗法区分开来. The company argues that the future of cannabis medicine must be built on evidence, not hype, distinguishing between general access and proven botanical therapies.